Company
Tempo Therapeutics
Pioneering a new era in tissue engineering biotechnology
Also known as Tempo Therapeutics, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- tempothera.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Using MAP technology, we are building functional tissue and organs within patients to treat disease.
Funding snapshot
- Total raised
- $20.2MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Undisclosed, $14.5M2026-09-16
Funding rounds
- Round, 2026
- $14.5M2026-09-16, Company stated
- Series A
- 2024-03-19
- Round, 2024
- $16.3M2024-03-01, SEC form D sold, 26 investors
- Round, 2020
- $3.8M2020-05-21, SEC form D sold, 39 investors
Products
- Other
- TT101
Loading relationship preview